These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Population pharmacokinetic investigation for optimization of amiodarone therapy in Japanese patients. Araki R; Yukawa E; Nakashima MN; Fukuchi H; Sasaki H; Yano K; Nakashima M Ther Drug Monit; 2011 Dec; 33(6):750-6. PubMed ID: 22105593 [TBL] [Abstract][Full Text] [Related]
4. Intravenous amiodarone. Med Lett Drugs Ther; 1995 Dec; 37(963):114-5. PubMed ID: 7500909 [No Abstract] [Full Text] [Related]
5. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. Chow MS Ann Pharmacother; 1996 Jun; 30(6):637-43. PubMed ID: 8792951 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. Vadiei K; Troy S; Korth-Bradley J; Chiang ST; Zimmerman JJ J Clin Pharmacol; 1997 Jul; 37(7):610-7. PubMed ID: 9243354 [TBL] [Abstract][Full Text] [Related]
7. Comparative bioavailability of a premixed, ready-to-use formulation of intravenous amiodarone with traditional admixture in healthy subjects. Cushing DJ; Adams MP; Cooper WD; Agha B; Souney PF J Clin Pharmacol; 2012 Feb; 52(2):214-21. PubMed ID: 21257800 [TBL] [Abstract][Full Text] [Related]
8. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Kowey PR; Levine JH; Herre JM; Pacifico A; Lindsay BD; Plumb VJ; Janosik DL; Kopelman HA; Scheinman MM Circulation; 1995 Dec; 92(11):3255-63. PubMed ID: 7586312 [TBL] [Abstract][Full Text] [Related]
9. Benefit and risks of long-term amiodarone therapy for sustained ventricular tachycardia/fibrillation: minimum of three-year follow-up in 145 patients. Myers M; Peter T; Weiss D; Nalos PC; Gang ES; Oseran DS; Mandel WJ Am Heart J; 1990 Jan; 119(1):8-14. PubMed ID: 2296879 [TBL] [Abstract][Full Text] [Related]
10. Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrophysiologic study. Klein LS; Fineberg N; Heger JJ; Miles WM; Kammerling JM; Chang MS; Zipes DP; Prystowsky EN Am J Cardiol; 1988 May; 61(13):1024-30. PubMed ID: 3364357 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter. Mao ZL; Townsend RW; Gao Y; Wheeler JJ; Kastrissios H; Keirns J J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of intravenous amiodarone in the short term treatment of recurrent sustained ventricular tachycardia and ventricular fibrillation. Schützenberger W; Leisch F; Kerschner K; Harringer W; Herbinger W Br Heart J; 1989 Nov; 62(5):367-71. PubMed ID: 2590589 [TBL] [Abstract][Full Text] [Related]
14. Renewed impact of lidocaine on refractory ventricular arrhythmias in the amiodarone era. Yoshie K; Tomita T; Takeuchi T; Okada A; Miura T; Motoki H; Ikeda U Int J Cardiol; 2014 Oct; 176(3):936-40. PubMed ID: 25201023 [TBL] [Abstract][Full Text] [Related]
15. [Amiodarone absorption and elimination after oral and intravenous administration in healthy individuals]. Gaete LE; Ortiz M; Soto J; Saavedra I Rev Med Chil; 1995 Jun; 123(6):713-9. PubMed ID: 8525224 [TBL] [Abstract][Full Text] [Related]